THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information
Objectives To evaluate, including through repeated renal biopsy, whether the different ISN/RPS classes of proliferative lupus nephritis (LN) have similar short- and long-term responses to immunosuppression and have distinct long-term prognosis. Methods Ninety-eight patients with new onset ISN/RPS pr...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A275 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Suppl 3 |
container_start_page | A275 |
container_title | Annals of the rheumatic diseases |
container_volume | 72 |
creator | Vandepapelière, J. Aydin, S. Depresseux, G. Cosyns, J.-P. Jadoul, M. Houssiau, F. A. |
description | Objectives To evaluate, including through repeated renal biopsy, whether the different ISN/RPS classes of proliferative lupus nephritis (LN) have similar short- and long-term responses to immunosuppression and have distinct long-term prognosis. Methods Ninety-eight patients with new onset ISN/RPS proliferative (III, IV-S or IV-G) LN were diagnosed in our institution between 2001 and 2011. Their baseline renal parameters and their primary response to immunosuppressive therapy were compared, based on quarterly collected data during the first year. Long-term followup (mean 76 months) was also available, as well as repeated renal biopsy data, performed in 45 patients after a mean period of 30 months. Activity (range 0-42) and chronicity (range 0-6) indices were computed according to the Morel-Maroger scoring system. Results While baseline mean 24-h proteinuria was higher in Class IV-G patients (n=50) compared to Class III (n=25) and Class IV-S (n=23) and while baseline mean activity index was lower in Class III versus Class IV-S and Class IV-G, serum creatinine, serum albumin and 24-h proteinuria improved similarly over the first year in the 3 pathological classes. Morover, biochemical data collected at last followup did not differ, nor did the activity/chronicity index on repeated renal biopsy, nor the rate of end-stage renal disease or death. Percentages of patients treated with cyclophosphamide, mycophenolate mofetil and azathioprine were similar in the 3 pathological groups. Conclusions Long-term clinical and pathological prognosis of new-onset proliferative LN, can not be predicted by baseline subsetting according to the ISN/RPS classification. Disclosure of Interest None Declared |
doi_str_mv | 10.1136/annrheumdis-2013-eular.851 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777911786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008739721</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1636-1780b9da2bad1f949cfece0e4905f100697f282a20780db6d5013d300e56077b3</originalsourceid><addsrcrecordid>eNqVkD1v2zAQhomiBeqm_Q9EOys5ihYpdQucLwOGG9RJhi4EJR1jOrLokFTQblmy9Vf2l5SKg6Brp8Mdnvde4CHkM4NDxrg40n3v1zhsWxuyHBjPcOi0PywL9oZM2FSU6SrgLZkAAM-mlZDvyYcQNmmFkpUT8vvq4hp4zv88Pq2GOmCM0fa39NK7zhr0OtoHpIthNwS6xN3a22gDPW4a59uRi47GNdL5ann0_XJFZ50OwRrbpJzr6YnDQHsXx3cPtkV6o7tB1x2Oh9vehWgbOu-N89vnwEfyzugu4KeXeUCuz06vZhfZ4tv5fHa8yGomuMiYLKGuWp3XumWmmlaNwQYBpxUUhgGISpq8zHUOCWxr0RbJTMsBsBAgZc0PyJf935139wOGqDZu8H2qVExKWbHUIBL1dU813oXg0aidt1vtfykGarSv_rGvRvvq2b5K9lM424dtiPjzNan9nRKSy0Itb2bqByzEKi-kgsQXe77ebv6n5y-nS6F2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777911786</pqid></control><display><type>article</type><title>THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information</title><source>BMJ Journals - NESLi2</source><creator>Vandepapelière, J. ; Aydin, S. ; Depresseux, G. ; Cosyns, J.-P. ; Jadoul, M. ; Houssiau, F. A.</creator><creatorcontrib>Vandepapelière, J. ; Aydin, S. ; Depresseux, G. ; Cosyns, J.-P. ; Jadoul, M. ; Houssiau, F. A.</creatorcontrib><description>Objectives To evaluate, including through repeated renal biopsy, whether the different ISN/RPS classes of proliferative lupus nephritis (LN) have similar short- and long-term responses to immunosuppression and have distinct long-term prognosis. Methods Ninety-eight patients with new onset ISN/RPS proliferative (III, IV-S or IV-G) LN were diagnosed in our institution between 2001 and 2011. Their baseline renal parameters and their primary response to immunosuppressive therapy were compared, based on quarterly collected data during the first year. Long-term followup (mean 76 months) was also available, as well as repeated renal biopsy data, performed in 45 patients after a mean period of 30 months. Activity (range 0-42) and chronicity (range 0-6) indices were computed according to the Morel-Maroger scoring system. Results While baseline mean 24-h proteinuria was higher in Class IV-G patients (n=50) compared to Class III (n=25) and Class IV-S (n=23) and while baseline mean activity index was lower in Class III versus Class IV-S and Class IV-G, serum creatinine, serum albumin and 24-h proteinuria improved similarly over the first year in the 3 pathological classes. Morover, biochemical data collected at last followup did not differ, nor did the activity/chronicity index on repeated renal biopsy, nor the rate of end-stage renal disease or death. Percentages of patients treated with cyclophosphamide, mycophenolate mofetil and azathioprine were similar in the 3 pathological groups. Conclusions Long-term clinical and pathological prognosis of new-onset proliferative LN, can not be predicted by baseline subsetting according to the ISN/RPS classification. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.851</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A275</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A275.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A275.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Vandepapelière, J.</creatorcontrib><creatorcontrib>Aydin, S.</creatorcontrib><creatorcontrib>Depresseux, G.</creatorcontrib><creatorcontrib>Cosyns, J.-P.</creatorcontrib><creatorcontrib>Jadoul, M.</creatorcontrib><creatorcontrib>Houssiau, F. A.</creatorcontrib><title>THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives To evaluate, including through repeated renal biopsy, whether the different ISN/RPS classes of proliferative lupus nephritis (LN) have similar short- and long-term responses to immunosuppression and have distinct long-term prognosis. Methods Ninety-eight patients with new onset ISN/RPS proliferative (III, IV-S or IV-G) LN were diagnosed in our institution between 2001 and 2011. Their baseline renal parameters and their primary response to immunosuppressive therapy were compared, based on quarterly collected data during the first year. Long-term followup (mean 76 months) was also available, as well as repeated renal biopsy data, performed in 45 patients after a mean period of 30 months. Activity (range 0-42) and chronicity (range 0-6) indices were computed according to the Morel-Maroger scoring system. Results While baseline mean 24-h proteinuria was higher in Class IV-G patients (n=50) compared to Class III (n=25) and Class IV-S (n=23) and while baseline mean activity index was lower in Class III versus Class IV-S and Class IV-G, serum creatinine, serum albumin and 24-h proteinuria improved similarly over the first year in the 3 pathological classes. Morover, biochemical data collected at last followup did not differ, nor did the activity/chronicity index on repeated renal biopsy, nor the rate of end-stage renal disease or death. Percentages of patients treated with cyclophosphamide, mycophenolate mofetil and azathioprine were similar in the 3 pathological groups. Conclusions Long-term clinical and pathological prognosis of new-onset proliferative LN, can not be predicted by baseline subsetting according to the ISN/RPS classification. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkD1v2zAQhomiBeqm_Q9EOys5ihYpdQucLwOGG9RJhi4EJR1jOrLokFTQblmy9Vf2l5SKg6Brp8Mdnvde4CHkM4NDxrg40n3v1zhsWxuyHBjPcOi0PywL9oZM2FSU6SrgLZkAAM-mlZDvyYcQNmmFkpUT8vvq4hp4zv88Pq2GOmCM0fa39NK7zhr0OtoHpIthNwS6xN3a22gDPW4a59uRi47GNdL5ann0_XJFZ50OwRrbpJzr6YnDQHsXx3cPtkV6o7tB1x2Oh9vehWgbOu-N89vnwEfyzugu4KeXeUCuz06vZhfZ4tv5fHa8yGomuMiYLKGuWp3XumWmmlaNwQYBpxUUhgGISpq8zHUOCWxr0RbJTMsBsBAgZc0PyJf935139wOGqDZu8H2qVExKWbHUIBL1dU813oXg0aidt1vtfykGarSv_rGvRvvq2b5K9lM424dtiPjzNan9nRKSy0Itb2bqByzEKi-kgsQXe77ebv6n5y-nS6F2</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Vandepapelière, J.</creator><creator>Aydin, S.</creator><creator>Depresseux, G.</creator><creator>Cosyns, J.-P.</creator><creator>Jadoul, M.</creator><creator>Houssiau, F. A.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information</title><author>Vandepapelière, J. ; Aydin, S. ; Depresseux, G. ; Cosyns, J.-P. ; Jadoul, M. ; Houssiau, F. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1636-1780b9da2bad1f949cfece0e4905f100697f282a20780db6d5013d300e56077b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vandepapelière, J.</creatorcontrib><creatorcontrib>Aydin, S.</creatorcontrib><creatorcontrib>Depresseux, G.</creatorcontrib><creatorcontrib>Cosyns, J.-P.</creatorcontrib><creatorcontrib>Jadoul, M.</creatorcontrib><creatorcontrib>Houssiau, F. A.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vandepapelière, J.</au><au>Aydin, S.</au><au>Depresseux, G.</au><au>Cosyns, J.-P.</au><au>Jadoul, M.</au><au>Houssiau, F. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A275</spage><pages>A275-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives To evaluate, including through repeated renal biopsy, whether the different ISN/RPS classes of proliferative lupus nephritis (LN) have similar short- and long-term responses to immunosuppression and have distinct long-term prognosis. Methods Ninety-eight patients with new onset ISN/RPS proliferative (III, IV-S or IV-G) LN were diagnosed in our institution between 2001 and 2011. Their baseline renal parameters and their primary response to immunosuppressive therapy were compared, based on quarterly collected data during the first year. Long-term followup (mean 76 months) was also available, as well as repeated renal biopsy data, performed in 45 patients after a mean period of 30 months. Activity (range 0-42) and chronicity (range 0-6) indices were computed according to the Morel-Maroger scoring system. Results While baseline mean 24-h proteinuria was higher in Class IV-G patients (n=50) compared to Class III (n=25) and Class IV-S (n=23) and while baseline mean activity index was lower in Class III versus Class IV-S and Class IV-G, serum creatinine, serum albumin and 24-h proteinuria improved similarly over the first year in the 3 pathological classes. Morover, biochemical data collected at last followup did not differ, nor did the activity/chronicity index on repeated renal biopsy, nor the rate of end-stage renal disease or death. Percentages of patients treated with cyclophosphamide, mycophenolate mofetil and azathioprine were similar in the 3 pathological groups. Conclusions Long-term clinical and pathological prognosis of new-onset proliferative LN, can not be predicted by baseline subsetting according to the ISN/RPS classification. Disclosure of Interest None Declared</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.851</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A275 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1777911786 |
source | BMJ Journals - NESLi2 |
title | THU0323 Subsettting Proliferative Lupus Nephritis According to the ISN/RPS Classification Does not Provide Valuable Prognostic Information |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T22%3A06%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0323%E2%80%85Subsettting%20Proliferative%20Lupus%20Nephritis%20According%20to%20the%20ISN/RPS%20Classification%20Does%20not%20Provide%20Valuable%20Prognostic%20Information&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Vandepapeli%C3%A8re,%20J.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A275&rft.pages=A275-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.851&rft_dat=%3Cproquest_cross%3E4008739721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777911786&rft_id=info:pmid/&rfr_iscdi=true |